Receipt of Observation letter with "No Adverse Observations" from BSE Limited in relation to Scheme of Arrangement between Meridian Medical Research & Hospital Ltd (Transferor Company) ....
Awaiting price reaction for this filing.
Narayana Hrudayalaya Limited has received a 'No Adverse Observations' letter from BSE on June 23, 2025 for its proposed Scheme of Arrangement with subsidiary Meridian Medical Research & Hospital Ltd (MMRHL). Under the scheme, MMRHL (the Transferor Company) will merge into Narayana Hrudayalaya (the Transferee Company) under Sections 230-232 of the Companies Act, 2013. The company's Board had first approved the scheme on November 29, 2024. BSE has flagged several disclosure requirements (valuation details, share-swap ratio, financial impact on shareholders, etc.) that must be included in the explanatory statement sent to shareholders. The observation letter is valid for six months, within which the company must file the scheme with the National Company Law Tribunal (NCLT). The scheme still requires NCLT approval, shareholder and creditor consent, and other regulatory clearances before it can take effect.
A positive procedural milestone — the merger of the subsidiary into the parent is now one step closer to completion, but it remains subject to NCLT and shareholder approvals. Key details like share-swap ratio and valuation impact on public shareholders are still awaited and will be critical for investor decision-making.